Multinodular Goiter

Endocrinology: Adult and Pediatric, Sixth Edition

Volumn 2, Issue , 2010, Pages 1636-1649

  Hegedüs, Laszlo ^a   Paschke, Ralf ^b   Krohn, Knut ^b   Bonnema, Steen J ^a  

^a ODENSE UNIVERSITY HOSPITAL   (Denmark)

^b UNIVERSITY HOSPITAL LEIPZIG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 78650069806     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-1-4160-5583-9.00087-3     Document Type: Chapter

References (159)

1. C Hedinger, ED Williams and LH Sobin (1989) The WHO histological classification of thyroid tumors: a commentary on the second edition. Cancer 63 908-911.
2. A Belfiore, GL La Rosa, GA La Porta, et al. (1992) Cancer risk in patients with cold thyroid nodules: relevance of iodine intake, sex, age, and multinodularity. Am J Med 93 363-369.
3. N Knudsen, H Perrild, E Christiansen, et al. (2000) Thyroid structure and size and two-year follow-up of solitary cold thyroid nodules in an unselected population with borderline iodine deficiency. Eur J Endocrinol 142 224-230.
4. JKC Chan, M Hirokawa, H Evans, et al. (2004) Follicular adenoma. RA DeLellis, RV Lloyd, PU Heitz, et al., (Eds) WHO Classification of Tumours. Pathology and Genetics of Tumours of Endocrine Organs Lyon: IARC Press 98-103.
5. A Berghout, WM Wiersinga, NJ Smits, et al. (1990) Interrelationships between age, thyroid volume, thyroid nodularity, and thyroid function in patients with sporadic nontoxic goiter. Am J Med 89 602-608.
6. N Knudsen, P Laurberg, H Perrild, et al. (2002) Risk factors for goiter and thyroid nodules. Thyroid 12 879-888.
7. B Pisarikova, I Herzig and J Riha (1996) [Inorganic anions with a potential goitrogenic effect in drinking water supply for humans and animals]. Vet Med (Praha) 41 33-39.
8. G Scanelli (2002) [Lithium thyrotoxicosis, Report of a case and review of the literature]. Recenti Prog Med 93 100-103.
9. TH Brix, PS Hansen, KO Kyvik, et al. (2000) Cigarette smoking and risk of clinically overt thyroid disease: a population-based twin case-control study. Arch Intern Med 160 661-666.
10. TH Brix, KO Kyvik and L Hegedüs (1999) Major role of genes in the etiology of simple goiter in females: a population-based twin study. J Clin Endocrinol Metab 84 3071-3075.
11. N Knudsen, I Bulow, P Laurberg, et al. (2002) Parity is associated with increased thyroid volume solely among smokers in an area with moderate to mild iodine deficiency. Eur J Endocrinol 146 39-43.
12. K Krohn, D Fuhrer, Y Bayer, et al. (2005) Molecular pathogenesis of euthyroid and toxic multinodular goiter. Endocr Rev 26 504-524.
13. PS Hansen, TH Brix, FN Bennedbæk, et al. (2004) Genetic and environmental causes of individual differences in thyroid size: a study of healthy Danish twins. J Clin Endocrinol Metab 89 2071-2077.
14. Y Bayer, S Neumann, B Meyer, et al. (2004) Genome-wide linkage analysis reveals evidence for four new susceptibility loci for familial euthyroid goiter. J Clin Endocrinol Metab 89 4044-4052.
15. GR Bignell, F Canzian, M Shayeghi, et al. (1997) Familial nontoxic multinodular thyroid goiter locus maps to chromosome 14q but does not account for familial nonmedullary thyroid cancer. Am J Hum Genet 61 1123-1130.
16. S Neumann, Y Bayer, A Reske, et al. (2003) Further indications for genetic heterogeneity of euthyroid familial goiter. J Mol Med 81 736-745.
17. TH Brix and L Hegedüs (2000) Genetic and environmental factors in the aetiology of simple goitre. Ann Med 32 153-156.
18. JP Geerdsen and P Hee (1982) Nontoxic goitre. I. Surgical complications and longterm prognosis. Acta Chir Scand 148 221-224.
19. S Piraneo, P Vitri, A Galimberti, et al. (1997) Ultrasonographic surveillance after surgery for euthyroid goitre in patients treated or not with thyroxine. Eur J Surg 163 21-26.
20. J Corral, C Martin, R Perez, et al. (1993) Thyroglobulin gene point mutation associated with non-endemic simple goitre. Lancet 341 462-464.
21. R Gonzalez-Sarmiento, J Corral, MT Mories, et al. (2001) Monoallelic deletion in the 5′ region of the thyroglobulin gene as a cause of sporadic nonendemic simple goiter. Thyroid 11 789-793.
22. LA Everett, B Glaser, JC Beck, et al. (1997) Pendred syndrome is caused by mutations in a putative sulphate transporter gene (PDS). Nat Genet 17 411-422.
23. S Masmoudi, I Charfedine, M Hmani, et al. (2000) Pendred syndrome: phenotypic variability in two families carrying the same PDS missense mutation. Am J Med Genet 90 38-44.
24. H Fujiwara, K Tatsumi, K Miki, et al. (1998) Recurrent T354P mutation of the Na+/I− symporter in patients with iodide transport defect. J Clin Endocrinol Metab 83 2940-2943.
25. A Matsuda and S Kosugi (1997) A homozygous missense mutation of the sodium /iodide symporter gene causing iodide transport defect. J Clin Endocrinol Metab 82 3966-3971.
26. S Neumann, H Willgerodt, F Ackermann, et al. (1999) Linkage of familial euthyroid goiter to the multinodular goiter-1 locus and exclusion of the candidate genes thyroglobulin, thyroperoxidase, and Na+/I− symporter. J Clin Endocrinol Metab 84 3750-3756.
27. F Capon, A Tacconelli, E Giardina, et al. (2000) Mapping a dominant form of multinodular goiter to chromosome Xp22. Am J Hum Genet 67 1004-1007.
28. MC Many, JF Denef, S Hamudi, et al. (1986) Effects of iodide and thyroxine on iodine-deficient mouse thyroid: a morphological and functional study. J Endocrinol 110 203-210.
29. E Raspe and JE Dumont (1995) Tonic modulation of dog thyrocyte H2O2 generation and I− uptake by thyrotropin through the cyclic adenosine 3′,5′-monophosphate cascade. Endocrinology 136 965-973.
30. K Krohn, S Wohlgemuth, H Gerber, et al. (2000) Hot microscopic areas of iodine deficient euthyroid goiters contain constitutively activating TSH receptor mutations. J Pathology 192 37-42.
31. R Abs, A Stevenaert and A Beckers (1994) Autonomously functioning thyroid nodules in a patient with a thyrotropin-secreting pituitary adenoma: possible cause–effect relationship. Eur J Endocrinol 131 355-358.
32. H Studer, G Huber, M Derwahl, et al. (1989) [The transformation of Basedow's struma into nodular goiter: a reason for recurrence of hyperthyroidism]. Schweiz Med Wochenschr 119 203-208.
33. NW Cheung and SC Boyages (1997) The thyroid gland in acromegaly: an ultrasonographic study. Clin Endocrinol (Oxf) 46 545-549.
34. JE Dumont, AM Ermans, C Maenhaut, et al. (1995) Large goitre as a maladaptation to iodine deficiency. Clin Endocrinol (Oxf ) 43 1-10.
35. J Maier, H van Steeg, C van Oostrom, et al. (2007) Iodine deficiency activates antioxidant genes and causes DNA damage in the thyroid gland of rats and mice. Biochim Biophys Acta 1773 990-999.
36. AC Gerard, S Poncin, B Caetano, et al. (2008) Iodine deficiency induces a thyroid stimulating hormone-independent early phase of microvascular reshaping in the thyroid. Am J Pathol 172 748-760.
37. AF Howie, JR Arthur, F Nicol, et al. (1998) Identification of a 57-kilodalton selenoprotein in human thyrocytes as thioredoxin reductase and evidence that its expression is regulated through the calcium-phosphoinositol signaling pathway. J Clin Endocrinol Metab 83 2052-2058.
38. AF Howie, SW Walker, B Akesson, et al. (1995) Thyroidal extracellular glutathione peroxidase: a potential regulator of thyroid-hormone synthesis. Biochem J 308 713-717.
39. A Demelash, JO Karlsson, M Nilsson, et al. (2004) Selenium has a protective role in caspase-3-dependent apoptosis induced by H2O2 in primary cultured pig thyrocytes. Eur J Endocrinol 150 841-849.
40. K Krohn, J Maier and R Paschke (2007) Mechanisms of disease: hydrogen peroxide, DNA damage and mutagenesis in the development of thyroid tumors. Nat Clin Pract Endocrinol Metab 3 713-720.
41. J Maier, H van Steeg, C van Oostrom, et al. (2006) Deoxyribonucleic acid damage and spontaneous mutagenesis in the thyroid gland of rats and mice. Endocrinology 147 3391-3397.
42. H van Steeg, LH Mullenders and J Vijg (2000) Mutagenesis and carcinogenesis in nucleotide excision repair-deficient XPA knock out mice. Mutat Res 450 167-180.
43. LC Cardoso, DC Martins, MD Figueiredo, et al. (2001) Ca(2+)/nicotinamide adenine dinucleotide phosphate-dependent H(2)O(2) generation is inhibited by iodide in human thyroids. J Clin Endocrinol Metab 86 4339-4343.
44. MS Cooke, MD Evans, M Dizdaroglu, et al. (2003) Oxidative DNA damage: mechanisms, mutation, and disease. FASEB Journal 17 1195-1214.
45. S Poncin, AC Gerard, M Boucquey, et al. (2008) Oxidative stress in the thyroid gland: from harmlessness to hazard depending on the iodine content. Endocrinology 149 424-433.
46. J Parma, L Duprez, J Van Sande, et al. (1993) Somatic mutations in the thyrotropin receptor gene cause hyperfunctioning thyroid adenomas. Nature 365 649-651.
47. D Führer, HP Holzapfel, P Wonerow, et al. (1997) Somatic mutations in the thyrotropin receptor gene and not in the Gs alpha protein gene in 31 toxic thyroid nodules. J Clin Endocrinol Metab 82 3885-3891.
48. NA Georgopoulos, GP Sykiotis, A Sgourou, et al. (2003) Autonomously functioning thyroid nodules in a former iodine-deficient area commonly harbor gain-of-function mutations in the thyrotropin signaling pathway. Eur J Endocrinol 149 287-292.
49. HI Gozu, R Bircan, K Krohn, et al. (2006) Similar prevalence of somatic TSH receptor and Gs alpha mutations in toxic thyroid nodules in geographical regions with different iodine supply in Turkey. Eur J Endocrinol 155 535-545.
50. G Vassart (2004) Activating mutations of the TSH receptor. Thyroid 14 86-87.
51. K Krohn and R Paschke (2001) Progress in understanding the etiology of thyroid autonomy. J Clin Endocrinol Metab 86 3336-3345.
52. M Garcia-Delgado, CJ Gonzalez-Navarro, MC Napal, et al. (1998) Higher sensitivity of denaturing gradient gel electrophoresis than sequencing in the detection of mutations in DNA from tumor samples. Biotechniques 24 72.
53. B Trulzsch, K Krohn, P Wonerow, et al. (1999) DGGE is more sensitive for the detection of somatic point mutations than direct sequencing. Biotechniques 27 266-268.
54. B Trülzsch, K Krohn, P Wonerow, et al. (2001) Detection of thyroid-stimulating hormone receptor and Gs alpha mutations in 75 toxic thyroid nodules by denaturing gradient gel electrophoresis. J Mol Med 78 684-691.
55. J Van Sande, J Parma, M Tonacchera, et al. (1995) Somatic and germline mutations of the TSH receptor gene in thyroid diseases. J Clin Endocrinol Metab 80 2577-2585.
56. A Dugrillon, G Bechtner, WM Uedelhoven, et al. (1990) Evidence that an iodolactone mediates the inhibitory effect of iodide on thyroid cell proliferation but not on adenosine 3′,5′-monophosphate formation. Endocrinology 127 337-343.
57. PP Roger, P Servais and JE Dumont (1983) Stimulation by thyrotropin and cyclic AMP of the proliferation of quiescent canine thyroid cells cultured in a defined medium containing insulin. FEBS Lett 157 323-329.
58. MC Eggo, LK Bachrach and GN Burrow (1990) Interaction of TSH, insulin and insulin-like growth factors in regulating thyroid growth and function. Growth Factors 2 99-109.
59. M Eszlinger, K Krohn, R Frenzel, et al. (2004) Gene expression analysis reveals evidence for inactivation of the TGF-beta signaling cascade in autonomously functioning thyroid nodules. Oncogene 23 795-804.
60. R Gärtner, D Schopohl, S Schaefer, et al. (1997) Regulation of transforming growth factor beta 1 messenger ribonucleic acid expression in porcine thyroid follicles in vitro by growth factors, iodine, or delta-iodolactone. Thyroid 7 633-640.
61. M Taton, F Lamy, PP Roger, et al. (1993) General inhibition by transforming growth factor beta 1 of thyrotropin and cAMP responses in human thyroid cells in primary culture. Mol Cell Endocrinol 95 13-21.
62. F Depoortere, I Pirson, J Bartek, et al. (2000) Transforming growth factor beta(1) selectively inhibits the cyclic AMP-dependent proliferation of primary thyroid epithelial cells by preventing the association of cyclin D3-cdk4 with nuclear p27(kip1). Mol Biol Cell 11 1061-1076.
63. B Grubeck-Loebenstein, G Buchan, R Sadeghi, et al. (1989) Transforming growth factor beta regulates thyroid growth. Role in the pathogenesis of nontoxic goiter. J Clin Invest 83 764-770.
64. K Krohn, P Emmrich, N Ott, et al. (1999) Increased thyroid epithelial cell proliferation in toxic thyroid nodules. Thyroid 9 241-246.
65. M Derwahl and H Studer (2001) Nodular goiter and goiter nodules: Where iodine deficiency falls short of explaining the facts. Exp Clin Endocrinol Diabetes 109 250-260.
66. H Studer, HJ Peter and H Gerber (1989) Natural heterogeneity of thyroid cells: the basis for understanding thyroid function and nodular goiter growth. Endocr Rev 10 125-135.
67. K Krohn, A Reske, F Ackermann, et al. (2001) Ras mutations are rare in solitary cold and toxic thyroid nodules. Clin Endocrinol 55 241-248.
68. O Dohan, Z Baloch, Z Banrevi, et al. (2001) Rapid communication: predominant intracellular overexpression of the Na(+)/I(−) symporter (NIS) in a large sampling of thyroid cancer cases. J Clin Endocrinol Metab 86 2697-2700.
69. O Dohan, A De la Vieja, V Paroder, et al. (2003) The sodium/iodide Symporter (NIS): characterization, regulation, and medical significance. Endocr Rev 24 48-77.
70. M Tonacchera, P Viacava, P Agretti, et al. (2002) Benign nonfunctioning thyroid adenomas are characterized by a defective targeting to cell membrane or a reduced expression of the sodium iodide symporter protein. J Clin Endocrinol Metab 87 352-357.
71. JT Dunn and AD Dunn (2001) Update on intrathyroidal iodine metabolism. Thyroid 11 407-414.
72. V Lazar, JM Bidart, B Caillou, et al. (1999) Expression of the Na+/I− symporter gene in human thyroid tumors: a comparison study with other thyroid-specific genes. J Clin Endocrinol Metab 84 3228-3234.
73. B Caillou, C Dupuy, L Lacroix, et al. (2001) Expression of reduced nicotinamide adenine dinucleotide phosphate oxidase (ThoX, LNOX, Duox) genes and proteins in human thyroid tissues. J Clin Endocrinol Metab 86 3351-3358.
74. JJ De Vijlder (2003) Primary congenital hypothyroidism: defects in iodine pathways. Eur J Endocrinol 149 247-256.
75. MA Pisarev, L Krawiec, GJ Juvenal, et al. (1994) Studies on the goiter inhibiting action of iodolactones. Eur J Pharmacol 258 33-37.
76. K Krohn and R Paschke (2001) Loss of heterozygosity at the thyroid peroxidase gene locus in solitary cold thyroid nodules. Thyroid 11 741-747.
77. K Krohn and R Paschke (2004) BRAF mutations are not an alternative explanation for the molecular etiology of ras mutation negative cold thyroid nodules. Thyroid 14 359-361.
78. M Xing, V Vasko, G Tallini, et al. (2004) BRAF T1796A transversion mutation in various thyroid neoplasms. J Clin Endocrinol Metab 89 1365-1368.
79. E Puxeddu, S Moretti, R Elisei, et al. (2004) BRAF(V599E) mutation is the leading genetic event in adult sporadic papillary thyroid carcinomas. J Clin Endocrinol Metab 89 2414-2420.
80. P Soares, V Trovisco, AS Rocha, et al. (2003) BRAF mutations and RET/PTC rearrangements are alternative events in the etiopathogenesis of PTC. Oncogene 22 4578-4580.
81. M Eszlinger, K Krohn, K Berger, et al. (2005) Gene expression analysis reveals evidence for increased expression of cell cycle-associated genes and Gq-protein-protein kinase C signaling in cold thyroid nodules. J Clin Endocrinol Metab 90 1163-1170.
82. K Krohn, I Stricker, P Emmrich, et al. (2003) Cold thyroid nodules show a marked increase of proliferation markers. Thyroid 13 569-576.
83. S Bol, G Belge, B Thode, et al. (1999) Structural abnormalities of chromosome 2 in benign thyroid tumors. Three new cases and review of the literature. Cancer Genet Cytogenet 114 75-77.
84. V Rippe, N Drieschner, M Meiboom, et al. (2003) Identification of a gene rearranged by 2p21 aberrations in thyroid adenomas. Oncogene 22 6111-6114.
85. LS Ward, G Brenta, M Medvedovic, et al. (1998) Studies of allelic loss in thyroid tumors reveal major differences in chromosomal instability between papillary and follicular carcinomas. J Clin Endocrinol Metab 83 525-530.
86. GH Tan, H Gharib and CC Reading (1995) Solitary thyroid nodule. Comparison between palpation and ultrasonography. Arch Intern Med 155 2418-2423.
87. L Hegedüs, SJ Bonnema and FN Bennedbæk (2003) Management of simple nodular goiter: current status and future perspectives. Endocr Rev 24 102-132.
88. MP Vanderpump, WM Tunbridge, JM French, et al. (1995) The incidence of thyroid disorders in the community: a twenty-year follow-up of the Whickham Survey. Clin Endocrinol (Oxf) 43 55-68.
89. P Laurberg, KM Pedersen, H Vestergaard, et al. (1991) High incidence of multinodular toxic goitre in the elderly population in a low iodine intake area vs. high incidence of Graves’ disease in the young in a high iodine intake area: comparative surveys of thyrotoxicosis epidemiology in East-Jutland Denmark and Iceland. J Intern Med 229 415-420.
90. A Berghout, WM Wiersinga, HA Drexhage, et al. (1990) Comparison of placebo with L-thyroxine alone or with carbimazole for treatment of sporadic non-toxic goitre. Lancet 336 193-197.
91. L Hegedüs (2001) Thyroid Ultrasound. Endocrinol Metab Clin North Am 30 339-360.
92. SR Tollin, GM Mery, N Jelveh, et al. (2000) The use of fine-needle aspiration biopsy under ultrasound guidance to assess the risk of malignancy in patients with a multinodular goiter. Thyroid 10 235-241.
93. F Aghini-Lombardi, L Antonangeli, E Martino, et al. (1999) The spectrum of thyroid disorders in an iodine-deficient community: the Pescopagano survey. J Clin Endocrinol Metab 84 561-566.
94. AE Jarløv, B Nygaard, L Hegedüs, et al. (1998) Observer variation in the clinical and laboratory evaluation of patients with thyroid dysfunction and goiter. Thyroid 8 393-398.
95. MI Surks, E Ortiz, GH Daniels, et al. (2004) Subclinical thyroid disease: scientific review and guidelines for diagnosis and management. JAMA 291 228-238.
96. R Elisei, V Bottici, F Luchetti, et al. (2004) Impact of routine measurement of serum calcitonin on the diagnosis and outcome of medullary thyroid cancer: experience in 10,864 patients with nodular thyroid disorders. J Clin Endocrinol Metab 89 163-168.
97. FN Bennedbæk, H Perrild and L Hegedüs (1999) Diagnosis and treatment of the solitary thyroid nodule. Results of a European survey. Clin Endocrinol (Oxf) 50 357-363.
98. FN Bennedbæk and L Hegedüs (2000) Management of the solitary thyroid nodule: results of a North American survey. J Clin Endocrinol Metab 85 2493-2498.
99. SJ Bonnema, FN Bennedbæk, WM Wiersinga, et al. (2000) Management of the nontoxic multinodular goitre: a European questionnaire study. Clin Endocrinol (Oxf) 53 5-12.
100. SJ Bonnema, FN Bennedbæk, PW Ladenson, et al. (2002) Management of the nontoxic multinodular goiter: a North American survey. J Clin Endocrinol Metab 87 112-117.
101. B Nygaard, L Hegedüs, P Ulriksen, et al. (1999) Radioiodine therapy for multinodular toxic goiter. Arch Intern Med 159 1364-1368.
102. B Nygaard, JH Knudsen, L Hegedüs, et al. (1997) Thyrotropin receptor antibodies and Graves’ disease, a side-effect of 131I treatment in patients with nontoxic goiter. J Clin Endocrinol Metab 82 2926-2930.
103. Y Okumura, Y Takeda, S Sato, et al. (1999) Comparison of differential diagnostic capabilities of 201Tl scintigraphy and fine-needle aspiration of thyroid nodules. J Nucl Med 40 1971-1977.
104. K Demirel, O Kapucu, C Yucel, et al. (2003) A comparison of radionuclide thyroid angiography, (99m)Tc-MIBI scintigraphy and power Doppler ultrasonography in the differential diagnosis of solitary cold thyroid nodules. Eur J Nucl Med Mol Imaging 30 642-650.
105. T Rago, F Santini, M Scutari, et al. (2007) Elastography: new developments in ultrasound for predicting malignancy in thyroid nodules. J Clin Endocrinol Metab 92 2917-2922.
106. FN Bennedbæk, S Karstrup and L Hegedüs (1997) Percutaneous ethanol injection therapy in the treatment of thyroid and parathyroid diseases. Eur J Endocrinol 136 240-250.
107. H Døssing, FN Bennedbæk and L Hegedüs (2005) Effect of ultrasound-guided interstitial laser photocoagulation on benign solitary solid cold thyroid nodules—a randomised study. Eur J Endocrinol 152 341-345.
108. FN Bennedbæk and L Hegedüs (2003) Treatment of recurrent thyroid cysts with ethanol: a randomized double-blind controlled trial. J Clin Endocrinol Metab 88 5773-5777.
109. FM Sebastianes, JJ Cerci, PH Zanoni, et al. (2007) Role of 18F-fluorodeoxyglucose positron emission tomography in preoperative assessment of cytologically indeterminate thyroid nodules. J Clin Endocrinol Metab 92 4485-4488.
110. KW Kang, SK Kim, HS Kang, et al. (2003) Prevalence and risk of cancer of focal thyroid incidentaloma identified by 18F-fluorodeoxyglucose positron emission tomography for metastasis evaluation and cancer screening in healthy subjects. J Clin Endocrinol Metab 88 4100-4104.
111. Z Baloch, VA Livolsi, P Jain, et al. (2003) Role of repeat fine-needle aspiration biopsy (FNAB) in the management of thyroid nodules. Diagn Cytopathol 29 203-206.
112. MR Haymart, DJ Repplinger, GE Leverson, et al. (2008) Higher serum thyroid stimulating hormone level in thyroid nodule patients is associated with greater risks of differentiated thyroid cancer and advanced tumor stage. J Clin Endocrinol Metab 93 809-814.
113. GH Tan and H Gharib (1997) Thyroid incidentalomas: management approaches to nonpalpable nodules discovered incidentally on thyroid imaging. Ann Intern Med 126 226-231.
114. E Papini, R Guglielmi, A Bianchini, et al. (2002) Risk of malignancy in nonpalpable thyroid nodules: predictive value of ultrasound and color-Doppler features. J Clin Endocrinol Metab 87 1941-1946.
115. MC Bhagat, SS Dhaliwal, SJ Bonnema, et al. (2003) Differences between endocrine surgeons and endocrinologists in the management of non-toxic multinodular goitre. Br J Surg 90 1103-1112.
116. T Watt, M Grønvold, AK Rasmussen, et al. (2006) Quality of life in patients with benign thyroid disorders. A review. Eur J Endocrinol 154 501-510.
117. AP Weetman (2007) Radioiodine treatment for benign thyroid diseases. Clin Endocrinol (Oxf) 66 757-764.
118. MA Walter, M Briel, M Christ-Crain, et al. (2007) Effects of antithyroid drugs on radioiodine treatment: systematic review and meta-analysis of randomised controlled trials. BMJ 334 514.
119. SJ Bonnema, FN Bennedbæk, J Gram, et al. (2003) Resumption of methimazole after 131I therapy of hyperthyroid diseases: effect on thyroid function and volume evaluated by a randomized clinical trial. Eur J Endocrinol 149 485-492.
120. G Kahaly, HP Dienes, J Beyer, et al. (1997) Randomized, double blind, placebo-controlled trial of low dose iodide in endemic goiter. J Clin Endocrinol Metab 82 4049-4053.
121. H Perrild, JM Hansen, L Hegedüs, et al. (1982) Triiodothyronine and thyroxine treatment of diffuse non-toxic goitre evaluated by ultrasonic scanning. Acta Endocrinol (Copenh) 100 382-387.
122. MF Wesche, MM Tiel-Van Buul, P Lips, et al. (2001) A randomized trial comparing levothyroxine with radioactive iodine in the treatment of sporadic nontoxic goiter. J Clin Endocrinol Metab 86 998-1005.
123. S Fast, SJ Bonnema and L Hegedüs (2008) The majority of Danish non-toxic goitre patients are ineligible for Levothyroxine suppressive therapy. Clin Endocrinol (Oxf) 69 653-658.
124. L Hegedüs (2004) The thyroid nodule. N Engl J Med 351 1764-1771.
125. DS Cooper, GM Doherty, BR Haugen, et al. (2006) Management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid 16 109-142.
126. Y Ito, T Uruno, K Nakano, et al. (2003) An observation trial without surgical treatment in patients with papillary microcarcinoma of the thyroid. Thyroid 13 381-387.
127. L Hegedüs, B Nygaard and JM Hansen (1999) Is routine thyroxine treatment to hinder postoperative recurrence of nontoxic goiter justified? J Clin Endocrinol Metab 84 756-760.
128. PV Pradeep, P Tiwari, A Mishra, et al. (2008) Pulmonary function profile in patients with benign goiters without symptoms of respiratory compromise and the early effect of thyroidectomy. J Postgrad Med 54 98-101.
129. D Erickson, H Gharib, H Li, et al. (1998) Treatment of patients with toxic multinodular goiter. Thyroid 8 277-282.
130. NN al Suliman, NF Ryttov, N Qvist, et al. (1997) Experience in a specialist thyroid surgery unit: a demographic study, surgical complications, and outcome. Eur J Surg 163 13-20.
131. O Thomusch, A Machens, C Sekulla, et al. (2000) Multivariate analysis of risk factors for postoperative complications in benign goiter surgery: prospective multicenter study in Germany. World J Surg 24 1335-1341.
132. AT Morrissey, J Chau, WK Yunker, et al. (2008) Comparison of drain versus no drain thyroidectomy: randomized prospective clinical trial. J Otolaryngol 37 43-47.
133. T Youssef, T Mahdy, M Farid, et al. (2008 May 23) Thyroid surgery: Use of the LigaSure Vessel Sealing System versus conventional knot tying. Int J Surg
134. G Torre, G Borgonovo, A Amato, et al. (1995) Surgical management of substernal goiter: analysis of 237 patients. Am Surg 61 826-831.
135. J Feldkamp, T Seppel, A Becker, et al. (1997) Iodide or L-thyroxine to prevent recurrent goiter in an iodine-deficient area: prospective sonographic study. World J Surg 21 10-14.
136. G Pappalardo, A Guadalaxara, FM Frattaroli, et al. (1998) Total compared with subtotal thyroidectomy in benign nodular disease: personal series and review of published reports. Eur J Surg 164 501-506.
137. JR Porterfield Jr, GB Thompson, DR Farley, et al. (2008) Evidence-based management of toxic multinodular goiter (Plummer's disease). World J Surg 32 1278-1284.
138. B Nygaard, L Hegedüs, M Gervil, et al. (1993) Radioiodine treatment of multinodular non-toxic goitre. Br Med J 307 828-832.
139. SJ Bonnema, H Bertelsen, J Mortensen, et al. (1999) The feasibility of high dose iodine 131 treatment as an alternative to surgery in patients with a very large goiter: effect on thyroid function and size and pulmonary function. J Clin Endocrinol Metab 84 3636-3641.
140. DA Huysmans, AR Hermus, FH Corstens, et al. (1994) Large, compressive goiters treated with radioiodine. Ann Intern Med 121 757-762.
141. SJ Bonnema, VE Nielsen and L Hegedüs (2004) Long-term effects of radioiodine on thyroid function, size and patient satisfaction in non-toxic diffuse goitre. Eur J Endocrinol 150 439-445.
142. AE Jarløv, L Hegedüs, LØ Kristensen, et al. (1995) Is calculation of the dose in radioiodine therapy of hyperthyroidism worth while? Clin Endocrinol (Oxf) 43 325-329.
143. B Nygaard, J Faber and L Hegedüs (1994) Acute changes in thyroid volume and function following 131I therapy of multinodular goitre. Clin Endocrinol (Oxf) 41 715-718.
144. E Ron, MM Doody, DV Becker, et al. (1998) Cancer mortality following treatment for adult hyperthyroidism. Cooperative Thyrotoxicosis Therapy Follow-up Study Group. JAMA 280 347-355.
145. JA Franklyn, P Maisonneuve, M Sheppard, et al. (1999) Cancer incidence and mortality after radioiodine treatment for hyperthyroidism: a population-based cohort study. Lancet 353 2111-2115.
146. S Metso, A Auvinen, H Huhtala, et al. (2007) Increased cancer incidence after radioiodine treatment for hyperthyroidism. Cancer 109 1972-1979.
147. DA Huysmans, WA Nieuwlaat, RJ Erdtsieck, et al. (2000) Administration of a single low dose of recombinant human thyrotropin significantly enhances thyroid radioiodide uptake in nontoxic nodular goiter. J Clin Endocrinol Metab 85 3592-3596.
148. VE Nielsen, SJ Bonnema, H Boel-Jørgensen, et al. (2005) Recombinant human thyrotropin markedly changes the 131I kinetics during 131I therapy of patients with nodular goiter: an evaluation by a randomized double-blinded trial. J Clin Endocrinol Metab 90 79-83.
149. CC Albino, CO Mesa Jr, M Olandoski, et al. (2005) Recombinant human thyrotropin as adjuvant in the treatment of multinodular goiters with radioiodine. J Clin Endocrinol Metab 90 2775-2780.
150. WA Nieuwlaat, AR Hermus, F Sivro-Prndelj, et al. (2001) Pretreatment with recombinant human TSH changes the regional distribution of radioiodine on thyroid scintigrams of nodular goiters. J Clin Endocrinol Metab 86 5330-5336.
151. SJ Bonnema, VE Nielsen, H Boel-Jørgensen, et al. (2007) Improvement of goiter volume reduction after 0.3 mg recombinant human thyrotropin-stimulated radioiodine therapy in patients with a very large goiter: a double-blinded, randomized trial. J Clin Endocrinol Metab 92 3424-3428.
152. VE Nielsen, SJ Bonnema, H Boel-Jørgensen, et al. (2006) Stimulation with 0.3-mg recombinant human thyrotropin prior to iodine 131 therapy to improve the size reduction of benign nontoxic nodular goiter: a prospective randomized double-blind trial. Arch Intern Med 166 1476-1482.
153. SJ Bonnema, VE Nielsen, H Boel-Jørgensen, et al. (2008) Recombinant human thyrotropin stimulated radioiodine therapy of large nodular goiters facilitates tracheal decompression and improves inspiration. J Clin Endocrinol Metab 93 3981-3984.
154. WA Nieuwlaat, DA Huysmans, HC Van Den Bosch, et al. (2003) Pretreatment with a single, low dose of recombinant human thyrotropin allows dose reduction of radioiodine therapy in patients with nodular goiter. J Clin Endocrinol Metab 88 3121-3129.
155. WA Nieuwlaat, AR Hermus, HA Ross, et al. (2004) Dosimetry of radioiodine therapy in patients with nodular goiter after pretreatment with a single, low dose of recombinant human thyroid-stimulating hormone. J Nucl Med 45 626-633.
156. VE Nielsen, SJ Bonnema and L Hegedüs (2006) Transient goiter enlargement after administration of 0.3 mg of recombinant human thyrotropin in patients with benign nontoxic nodular goiter: a randomized, double-blind, crossover trial. J Clin Endocrinol Metab 91 1317-1322.
157. VE Nielsen, SJ Bonnema and L Hegedüs (2004) Effects of 0.9 mg recombinant human thyrotropin on thyroid size and function in normal subjects: a randomized, double-blind, cross-over trial. J Clin Endocrinol Metab 89 2242-2247.
158. O Cohen, J Ilany, C Hoffman, et al. (2006) Low-dose recombinant human thyrotropin-aided radioiodine treatment of large, multinodular goiters in elderly patients. Eur J Endocrinol 154 243-252.
159. MN Silva, IG Rubio, R Romao, et al. (2004) Administration of a single dose of recombinant human thyrotrophin enhances the efficacy of radioiodine treatment of large compressive multinodular goitres. Clin Endocrinol (Oxf) 60 300-308.